Bone density and body composition in chronic renal failure: effects of growth hormone treatment.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

Metabolic bone disease and growth retardation are common complications of chronic renal failure (CRF).

The researchers evaluated bone mineral density (BMD), bone metabolism, body composition and growth in children with CRF, and the effect of growth hormone treatment (GHRx) on these variables.

Who Took Part

The abstract describes 18 children taking part.

PubMed indexes the participants as young children and children, both men and women.

How the Study Was Run

Every 6 months, BMD of lumbar spine and total body, and body composition were measured by dual-energy X-ray absorptiometry.

Biochemical parameters of bone turnover were assessed.

What Was Measured

The researchers evaluated bone mineral density (BMD), bone metabolism, body composition and growth in children with CRF, and the effect of growth hormone treatment (GHRx) on these variables.

The subject headings attached to it are Age Determination by Skeleton, Biomarkers, Body Composition, Body Height, Bone Density, Bone and Bones and Growth Disorders.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2000 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.